摘要 |
Abstract The present invention is based, in part, on the identification of novel human anti-PD 1, PD-Li, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-Li, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-Li, and PD-L2 antibodies described herein. 8131965_1 (GHMatters) P86720.AU.3 |
申请人 |
Emory University;DANA-FARBER CANCER INSTITUTE, INC. |
发明人 |
FREEMAN, Gordon J.;AHMED, Rafi;JONES, Timothy D.;CARR, Francis J.;GREGSON, James P. |